Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lemonex Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units, showing that each pending matter is being reviewed by a different examiner in a different administrative division. This spread suggests that the company's active biotechnology filings may cover diverse technical subjects, requiring a varied approach to legal arguments and technical documentation.
The busiest examiner for the portfolio is SONG, JIANFENG, who is handling 1 pending office action. This represents one of the 2 pending office actions total for the company. The involvement of 2 distinct art units means that the company must manage its prosecution across two different sets of examination guidelines and administrative teams within the biotechnology and pharmaceutical sector. This decentralized structure requires the company to be versatile in its prosecution approach, addressing the unique requirements of two different examiners and two different art units simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.4% | +33.0% |
| HARTLEY, MICHAEL G | 1 | 38.0% | +74.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 34d |
| 18910379 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18910379 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | SONG, JIANFENG | 1613 | §102§103DP | Non-Final OA | — | Pending | Oct 09, 2024 |
| 17264944 | POLYPEPTIDE DELIVERY COMPOSITION | HARTLEY, MICHAEL G | 1618 | §103§112 | Non-Final OA | 34d | Pending | Feb 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLemonex Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jianfeng Song has the most, with 1 of Lemonex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
